Fetal Growth and Gestational Factors As Predictors of Schizophrenia in 22q11.2 Deletion Syndrome

Overview

Journal Genet Med

Publisher Elsevier

Specialty Genetics

Date 2015 Jun 19

PMID 26087175

Citations 14

Authors

Lily Van

Nancy J Butcher

Gregory Costain

Lucas Ogura

Eva W C Chow

Anne S Bassett

Affiliations

Soon will be listed here.

Abstract

Purpose: Schizophrenia occurs in 20-25% of adults with 22q11.2 deletion syndrome (22q11.2DS). General population studies of schizophrenia report associations with perinatal complications, although effect sizes are generally low. We aimed to determine whether such factors are associated with expression of schizophrenia in individuals with 22q11.2DS.

Methods: We investigated the relationship of small for gestational age (SGA) birth weight (<3rd percentile for sex and gestational age) and prematurity (<37 weeks gestation) to expression of schizophrenia in a well-characterized cohort of 123 adults with 22q11.2DS. Outcome measures included adjusted odds ratios and positive and negative predictive values (PPV and NPV) for schizophrenia.

Results: SGA birth weight (OR = 3.52, 95% CI = 1.34-9.22) and prematurity (OR = 5.38, 95% CI = 1.63-17.75), but not maternal factors, were significant risk factors for schizophrenia in 22q11.2DS. Being born SGA or premature resulted in a PPV of 46% for schizophrenia; NPV in the absence of both features was 83%. Post hoc analyses suggested these perinatal complications were also associated with factors indicative of increased severity of schizophrenia.

Conclusion: In 22q11.2DS, fetal growth and gestation may have a clinically significant impact on future risk for schizophrenia. These data advance our understanding of determinants of disease-specific expression in 22q11.2DS, with implications for other genomic disorders.Genet Med 18 4, 350-355.

Citing Articles

Clinically Relevant Genetic Considerations for Patients With Tetralogy of Fallot.

Bassett A, Reuter M, Malecki S, Silversides C, Oechslin E CJC Pediatr Congenit Heart Dis. 2024; 2(6Part A):426-439.

PMID: 38161665 PMC: 10755827. DOI: 10.1016/j.cjcpc.2023.10.002.

Positive cfDNA screening results for 22q11.2 deletion syndrome-Clinical and laboratory considerations.

Soster E, Dyr B, Rafalko J, Almasri E, Cacheris P Front Genet. 2023; 14:1146669.

PMID: 36968594 PMC: 10036386. DOI: 10.3389/fgene.2023.1146669.

Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions.

Blagowidow N, Nowakowska B, Schindewolf E, Grati F, Putotto C, Breckpot J Genes (Basel). 2023; 14(1).

PMID: 36672900 PMC: 9858737. DOI: 10.3390/genes14010160.

Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: a cross-sectional analysis from population-based newborn screening.

Blagojevic C, Heung T, Theriault M, Tomita-Mitchell A, Chakraborty P, Kernohan K CMAJ Open. 2021; 9(3):E802-E809.

PMID: 34404688 PMC: 8373039. DOI: 10.9778/cmajo.20200294.

Identifying neurodevelopmental anomalies of white matter microstructure associated with high risk for psychosis in 22q11.2DS.

Bagautdinova J, Padula M, Zoller D, Sandini C, Schneider M, Schaer M Transl Psychiatry. 2020; 10(1):408.

PMID: 33235187 PMC: 7686319. DOI: 10.1038/s41398-020-01090-z.

References

Reynaud R, Derain-Court J, Braunstein D, Veyrat M, Gaudart J, Giuliano F . Auxological evaluation in patients with a 22q11.2 microdeletion syndrome: normal prevalence of obesity and neonatal length and gender influence on body mass index evolution. Horm Res Paediatr. 2011; 76(3):172-7. DOI: 10.1159/000328454. View

Butcher N, Fung W, FitzPatrick L, Guna A, Andrade D, Lang A . Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry. 2015; 206(6):484-91. PMC: 4459828. DOI: 10.1192/bjp.bp.114.151837. View

Miller D, Adam M, Aradhya S, Biesecker L, Brothman A, Carter N . Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010; 86(5):749-64. PMC: 2869000. DOI: 10.1016/j.ajhg.2010.04.006. View

Jensen T, Dzakula Z, Deciu C, Van Den Boom D, Ehrich M . Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. Clin Chem. 2012; 58(7):1148-51. DOI: 10.1373/clinchem.2011.180794. View

Resnik R . Intrauterine growth restriction. Obstet Gynecol. 2002; 99(3):490-6. DOI: 10.1016/s0029-7844(01)01780-x. View

Brzustowicz L, Bassett A . miRNA-mediated risk for schizophrenia in 22q11.2 deletion syndrome. Front Genet. 2012; 3:291. PMC: 3521194. DOI: 10.3389/fgene.2012.00291. View

von Beckerath A, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P . Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. Am J Obstet Gynecol. 2012; 208(2):130.e1-6. DOI: 10.1016/j.ajog.2012.11.014. View

Campbell M, Cartier S, Xie B, Kouniakis G, Huang W, Han V . Determinants of small for gestational age birth at term. Paediatr Perinat Epidemiol. 2012; 26(6):525-33. DOI: 10.1111/j.1365-3016.2012.01319.x. View

Nosarti C, Reichenberg A, Murray R, Cnattingius S, Lambe M, Yin L . Preterm birth and psychiatric disorders in young adult life. Arch Gen Psychiatry. 2012; 69(6):E1-8. DOI: 10.1001/archgenpsychiatry.2011.1374. View

10.

Kugelman A, Colin A . Late preterm infants: near term but still in a critical developmental time period. Pediatrics. 2013; 132(4):741-51. DOI: 10.1542/peds.2013-1131. View

11.

Lee P, Chernausek S, Hokken-Koelega A, Czernichow P . International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics. 2003; 111(6 Pt 1):1253-61. DOI: 10.1542/peds.111.6.1253. View

12.

Robinson D, Woerner M, McMeniman M, Mendelowitz A, Bilder R . Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004; 161(3):473-9. DOI: 10.1176/appi.ajp.161.3.473. View

13.

Levine T, Grunau R, McAuliffe F, Pinnamaneni R, Foran A, Alderdice F . Early childhood neurodevelopment after intrauterine growth restriction: a systematic review. Pediatrics. 2014; 135(1):126-41. DOI: 10.1542/peds.2014-1143. View

14.

Fung W, McEvilly R, Fong J, Silversides C, Chow E, Bassett A . Elevated prevalence of generalized anxiety disorder in adults with 22q11.2 deletion syndrome. Am J Psychiatry. 2010; 167(8):998. PMC: 4516404. DOI: 10.1176/appi.ajp.2010.09101463. View

15.

Wapner R, Martin C, Levy B, Ballif B, Eng C, Zachary J . Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med. 2012; 367(23):2175-84. PMC: 3549418. DOI: 10.1056/NEJMoa1203382. View

16.

Merico D, Costain G, Butcher N, Warnica W, Ogura L, Alfred S . MicroRNA Dysregulation, Gene Networks, and Risk for Schizophrenia in 22q11.2 Deletion Syndrome. Front Neurol. 2014; 5:238. PMC: 4240070. DOI: 10.3389/fneur.2014.00238. View

17.

Forsyth J, Ellman L, Tanskanen A, Mustonen U, Huttunen M, Suvisaari J . Genetic risk for schizophrenia, obstetric complications, and adolescent school outcome: evidence for gene-environment interaction. Schizophr Bull. 2012; 39(5):1067-76. PMC: 3756777. DOI: 10.1093/schbul/sbs098. View

18.

Bassett A, Chow E, Husted J, Weksberg R, Caluseriu O, Webb G . Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A. 2005; 138(4):307-13. PMC: 3127862. DOI: 10.1002/ajmg.a.30984. View

19.

Kunugi H, Nanko S, Murray R . Obstetric complications and schizophrenia: prenatal underdevelopment and subsequent neurodevelopmental impairment. Br J Psychiatry Suppl. 2001; 40:s25-9. DOI: 10.1192/bjp.178.40.s25. View

20.

Svensson A, Pawitan Y, Cnattingius S, Reilly M, Lichtenstein P . Familial aggregation of small-for-gestational-age births: the importance of fetal genetic effects. Am J Obstet Gynecol. 2006; 194(2):475-9. DOI: 10.1016/j.ajog.2005.08.019. View